Workflow
ZJJF(600668)
icon
Search documents
尖峰集团:恩格列净获得化学原料药上市申请批准通知书
Ge Long Hui· 2025-07-29 09:30
格隆汇7月29日丨尖峰集团(600668.SH)公布,全资子公司浙江尖峰药业有限公司收到国家药品监督管理 局关于化学原料药恩格列净的《化学原料药上市申请批准通知书》。恩格列净是一种钠-葡萄糖协同转 运蛋白2(SGLT2)抑制剂。与运动和饮食结合,作为改善II型糖尿病成年患者的血糖控制的辅助治疗。恩 格列净能够阻断肾脏中葡萄糖的再吸收作用,将过多的葡萄糖排泄到体外,从而达到降低血糖水平的效 果,而且该降糖效果不依赖于β细胞功能和胰岛素抵抗。截至本公告日,恩格列净在CDE原辅包登记信 息平台显示状态为"A"的企业共二十八家,为江苏豪森药业集团有限公司、浙江华海药业股份有限公司 等。 ...
尖峰集团:子公司尖峰药业获得恩格列净化学原料药上市申请批准通知书
Xin Lang Cai Jing· 2025-07-29 09:12
尖峰集团(600668.SH)公告称,全资子公司尖峰药业收到国家药品监督管理局关于化学原料药恩格列净 的《化学原料药上市申请批准通知书》,该原料药已符合国家相关原料药审评技术标准,可在国内市场 进行销售,有助于拓展业务领域。但需注意医药产品具有高科技、高风险、高附加值的特点,药品的生 产和销售容易受到国家政策、市场环境变化等因素影响,存在较大不确定性。 ...
“反内卷”大幕拉开,资金抢筹钢铁、有色、建材行业股票
Huan Qiu Wang· 2025-07-24 03:44
【环球网财经综合报道】一场针对行业"内卷"的治理正在中国多个传统产业掀起波澜。自今年政策层面密集发声整治"内卷式"竞争以来,工业和信息化部近 期更是明确将实施新一轮钢铁、有色金属、石化、建材等十大重点行业稳增长工作方案,为推动行业调结构、优供给、淘汰落后产能。光伏、水泥、钢铁等 行业已率先响应,减产行动迅速展开。 " 反内卷 " 行动带来结构性机遇 政策发力去产能、优结构,正为相关行业带来新的发展契机。传统的基建行业如钢铁、有色金属和建材,正成为机构看好的投资"洼地"。政策旨在清除无效 供给,提升行业集中度,这预示着优质企业将迎来更好的发展环境。 部分已盈利的公司今年上半年业绩更上一层楼,三和管桩、万年青、北方稀土等净利润同比预增幅度居前。三和管桩净利润预计同比增长高达30.91倍至 38.89倍,主要得益于产品矩阵丰富、成本管控优化和产品结构改善。 市场资金加速流入 业绩的改善直接点燃了市场热情。数据显示,上述68只业绩预增的基建股在7月平均上涨15.82%,其中柳钢股份、盛和资源、华新水泥、三和管桩、中材科 技、北方稀土累计涨幅均超40%,柳钢股份更是以121.31%的累计涨幅高居榜首。 从估值角度看,截 ...
7月21日早间新闻精选
news flash· 2025-07-21 00:29
Group 1 - The Yarlung Tsangpo River downstream hydropower project has officially commenced with a total investment of approximately 1.2 trillion yuan, aiming to build five tiered power stations primarily for electricity transmission and local consumption in Tibet [1] - The Ministry of Industry and Information Technology (MIIT) plans to accelerate the development of biomanufacturing and low-altitude industries, while promoting innovation in future industries such as humanoid robots and brain-computer interfaces [2][3] - The MIIT and the National Development and Reform Commission (NDRC) are set to issue work plans to stabilize growth in key industries including steel, non-ferrous metals, petrochemicals, and building materials [2][3] Group 2 - The U.S. Department of Commerce has imposed a preliminary anti-dumping duty of 93.5% on Chinese imported anode-grade graphite, citing unfair subsidies [5] - The State Administration for Market Regulation has urged major platform companies like Ele.me, Meituan, and JD.com to standardize promotional activities and foster a healthy competitive environment in the food service industry [6] - A meeting was held to discuss the regulation of the new energy vehicle industry, focusing on enhancing supervision and monitoring product prices and quality [8] Group 3 - The China Iron and Steel Association has proposed a new mechanism for capacity governance to prevent overcapacity risks in the steel industry and to eliminate irrational competition [10] - Yu Shu Technology has initiated its listing guidance, with its controlling shareholder holding approximately 34.76% of the company's shares [11] - Multiple provinces are planning to establish companies to develop local cultural creative Moutai liquor, with participation from distributors based on their allocation of Moutai products [12] Group 4 - As of July 18, 1551 A-share listed companies have released performance forecasts for the first half of 2025, with 26 companies expecting a net profit increase of over 1000% year-on-year [14] - Longhua Automobile reported a net profit of 6.337 billion yuan for the first half of the year, reflecting a year-on-year decline of 10.22% [19] - The major shareholder of Hongbaoli plans to reduce its stake by up to 2% [20]
尖峰集团: 尖峰集团关于实施2024年年度权益分派后调整回购股份价格上限的公告
Zheng Quan Zhi Xing· 2025-07-15 08:13
Core Viewpoint - The company has announced an adjustment to the maximum repurchase price of its shares following the implementation of the 2024 annual equity distribution, reducing it from RMB 15.00 per share to RMB 12.42 per share, effective from July 15, 2025 [1][2]. Group 1: Share Repurchase Plan - The company plans to repurchase shares using its own and raised funds through centralized bidding, with a total expected repurchase amount of no less than RMB 20 million [1][2]. - The maximum repurchase price was initially set at RMB 15.00 per share but has been adjusted to RMB 12.42 per share due to the distribution of cash dividends and capital reserve conversion [2][3]. - The repurchase will be based on the total share capital minus the shares held in the repurchase account, with a cash dividend of RMB 0.1 per share and a capital reserve conversion of 0.2 shares per share [2]. Group 2: Adjustment Calculation - The adjusted maximum repurchase price is calculated as follows: (15.00 - 0.1) ÷ (1 + 0.2) ≈ 12.42 RMB per share [2]. - The expected maximum number of shares to be repurchased is approximately 1.61 million shares, representing 0.39% of the company's current total share capital [2]. Group 3: Compliance and Disclosure - The company will adhere to relevant regulations and guidelines during the repurchase process and will disclose information regarding the progress of the repurchase in a timely manner [3].
尖峰集团(600668) - 尖峰集团关于实施2024年年度权益分派后调整回购股份价格上限的公告
2025-07-15 07:46
证券简称:尖峰集团 证券代码:600668 编号:临 2025-034 浙江尖峰集团股份有限公司 关于实施 2024 年年度权益分派后 调整回购股份价格上限的公告 浙江尖峰集团股份有限公司(以下简称"公司")于 2025 年 4 月 18 日召开 了第十二届董事会第 7 次会议,审议通过了《关于以集中竞价交易方式回购公司 股份方案的议案》,同意公司使用自有资金及自筹资金以集中竞价交易方式回购 公司股份,用于员工持股计划或股权激励,预计回购股份的资金总额为人民币 2,000 万元(含)-4,000 万元(含),回购期限为自公司董事会审议通过本次回 购股份方案之日起 12 个月内,回购价格不超过人民币 15.00 元/股(含),若在 回购实施期限内,公司发生资本公积金转增股本、派送股票或现金红利等除权除 息事项,自股价除权除息之日起,相应调整回购股份价格上限。具体内容详见公 司于 2025 年 4 月 22 日在上海证券交易所网站(www.sse.com.cn)披露的《尖峰 集团关于以集中竞价交易方式回购公司股份方案的公告》(临 2025-014)。 二、调整回购股份价格上限的原因 2025 年 5 月 22 日 ...
利好!多股预增超10倍!
Zheng Quan Shi Bao· 2025-07-14 15:11
Group 1 - The first half of 2025 financial reports for A-share companies have been released, with many companies forecasting profit increases of over 10 times [1][5] - Zhongyan Chemical's report shows a revenue of 5.998 billion yuan, a year-on-year decrease of 5.76%, and a net profit of 52.7155 million yuan, down 88.04% year-on-year [3][4] - The decline in Zhongyan Chemical's revenue is attributed to intensified market competition and significant price drops in key products, despite a 38.82% increase in sales volume [3][4] Group 2 - Huahong Technology expects a net profit of 70 million to 85 million yuan for the first half of 2025, representing a year-on-year increase of 3047.48% to 3721.94% [6] - Wan Nianqing anticipates a net profit of 31 million to 45 million yuan, reflecting a year-on-year growth of 1954.07% to 2881.71% [7] - Other companies such as Yatai Pharmaceutical and Aerospace Science and Technology also project significant profit increases, with Yatai expecting a net profit of 100 million to 110 million yuan, up 1726.42% to 1909.06% year-on-year [7]
利好!多股预增超10倍!
证券时报· 2025-07-14 14:52
Core Viewpoint - The first half of 2025 financial reports from A-share listed companies reveal significant profit increases, with several companies projecting profit growth exceeding tenfold compared to the previous year [1][5]. Group 1: Company Performance - Zhongyan Chemical's 2025 half-year report shows a revenue of 5.998 billion yuan, a decrease of 5.76% year-on-year, with a net profit of 52.7155 million yuan, down 88.04% year-on-year [3][4]. - The decline in Zhongyan Chemical's revenue is attributed to intensified market competition and significant price drops in key products like soda ash and PVC, despite a 38.82% increase in sales volume [3][4]. - Huahong Technology expects a net profit of 70 million to 85 million yuan for the first half of 2025, representing a year-on-year increase of 3047.48% to 3721.94%, driven by improved prices of rare earth raw materials [6][7]. - Wannianqing anticipates a net profit of 31 million to 45 million yuan, reflecting a year-on-year growth of 1954.07% to 2881.71%, supported by recovering demand in the cement industry and cost reduction efforts [6][7]. - Other companies like Yatai Pharmaceutical and Aerospace Science and Technology also project substantial profit increases, with expected growth rates of 1726.42% to 1909.06% and 1628.83% to 2315.27%, respectively [7]. Group 2: Market Trends - The overall trend indicates a recovery in certain sectors, such as the cement industry, due to reduced declines in real estate investment and infrastructure spending [7]. - The chemical industry is experiencing price fluctuations, with some products seeing significant price drops due to weakened downstream demand, while others like caustic soda have increased prices due to demand pull [4].
尖峰集团(600668) - 尖峰集团关于子公司终止临床试验的公告
2025-07-14 07:45
浙江尖峰集团股份有限公司 关于子公司终止临床试验的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 浙江尖峰药业有限公司(以下简称"尖峰药业")决定终止注射用去氧鬼 臼毒素(以下简称"DPT")临床试验及后续开发,并根据《企业会计准则》等相 关规定,基于会计谨慎性原则,将该项目计入"开发支出"的研发投入金额 1821.41 万元全额计提资产减值准备,预计将减少公司 2025 年半年度利润总额 1821.41 万元(未经审计)。 风险提示:公司重视药品研发,并严格控制研发成本,但由于创新药研 发存在高科技、高风险的特点,前期研发以及产品从研制、临床试验报批到投产 的周期长、环节多,易受不可预测的因素影响,研发风险不可避免,敬请广大投 资者谨慎决策,注意防范投资风险。 浙江尖峰集团股份有限公司(以下简称"本公司")的全资子公司尖峰药业 研发的 DPT 项目处于 I 期临床试验阶段,基于临床试验初步研究结果,经对项目 进展情况、后续开发前景和研发投入风险等因素进行综合评估后,经公司十二届 董事会第 10 次 ...
尖峰集团(600668) - 尖峰集团十二届10次董事会决议公告
2025-07-14 08:00
证券代码:600668 证券简称:尖峰集团 编号:临 2025-031 浙江尖峰集团股份有限公司 十二届10次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 公司第十二届董事会第 10 次会议决议 特此公告 浙江尖峰集团股份有限公司 通过了《关于子公司终止临床试验的议案》 经审议与表决,董事会通过了《关于子公司终止临床试验的议案》。 表决结果:9票同意、0票反对、0票弃权。 详见《尖峰集团关于子公司终止临床试验的公告》(临 2025-032)。 三、相关附件 (一)本次董事会会议的召集、召开符合有关法律、法规及《公司章程》的 相关规定。 (二)2025 年 07 月 14 日,本次董事会会议以通讯表决的方式召开。 (三)公司现有九名董事,全体董事出席了会议。 二、董事会会议审议情况 董事会 二〇二五年七月十五日 1 ...